While the rapid evolution of I-O continues to bring unprecedented change to the way cancer is treated, there are significant gaps impacting the laboratory team regarding the examination of resection specimens following neoadjuvant immunotherapy and staying abreast of advances in I-O biomarker testing. This episode discusses advances in I-O biomarker testing, advantages and limitations of some key I-O biomarkers, and practical ways that pathologists and laboratory professionals can improve their I-O biomarker testing workflows to optimize patient care. Topics discussed include: Recent advances in immune-oncology (I-O) biomarker testing Advantages and limitations of IO biomarkers Addressing challenges related to IO biomarkers Improving IO biomarker workflows Best practices for collaboration with the multidisciplinary cancer care team

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related